Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
Weycker D, Yu EB, Woolley JM, Oster G. Weycker D, et al. Among authors: yu eb. Clin Ther. 2005 May;27(5):646-56. doi: 10.1016/s0149-2918(05)00090-1. Clin Ther. 2005. PMID: 15978314
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Frankel EH, Strober BE, Crowley JJ, Fivenson DP, Woolley JM, Yu EB, Xia HA, Chiou CF, Stevens SR. Frankel EH, et al. Among authors: yu eb. Cutis. 2007 Apr;79(4):322-6. Cutis. 2007. PMID: 17500381 Clinical Trial.
Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.
Bullano MF, McNeeley BJ, Yu YF, Quimbo R, Burawski LP, Yu EB, Woolley JM. Bullano MF, et al. Among authors: yu eb. Manag Care Interface. 2006 Sep;19(9):47-53. Manag Care Interface. 2006. PMID: 17017313
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM. Schiff MH, et al. Among authors: yu eb. Drugs Aging. 2006;23(2):167-78. doi: 10.2165/00002512-200623020-00006. Drugs Aging. 2006. PMID: 16536638
Service setting impact on costs for bevacizumab-treated oncology patients.
Engel-Nitz NM, Yu EB, Becker LK, Small A. Engel-Nitz NM, et al. Among authors: yu eb. Am J Manag Care. 2014 Nov 1;20(11):e515-22. Am J Manag Care. 2014. PMID: 25730350 Free article.
Mechanistic insight into TRIP13-catalyzed Mad2 structural transition and spindle checkpoint silencing.
Brulotte ML, Jeong BC, Li F, Li B, Yu EB, Wu Q, Brautigam CA, Yu H, Luo X. Brulotte ML, et al. Among authors: yu eb. Nat Commun. 2017 Dec 5;8(1):1956. doi: 10.1038/s41467-017-02012-2. Nat Commun. 2017. PMID: 29208896 Free PMC article.
Feedback